Expanding paclitaxel's therapeutic window: Investigating the pharmacokinetic, clinical formulation and mechanistic aspects of paclitaxel‑lipoate conjugate

Abu‑Lafi,Saleh; Falah,Mizied; Zeidan,Mouhammad; Rayan,Mahmoud; Rayan,Anwar

doi:10.3892/ol.2025.14962

Expanding paclitaxel's therapeutic window: Investigating the pharmacokinetic, clinical formulation and mechanistic aspects of paclitaxel‑lipoate conjugate

Authors:
- Saleh Abu‑Lafi
- Mizied Falah
- Mouhammad Zeidan
- Mahmoud Rayan
- Anwar Rayan
View Affiliations

Affiliations: Faculty of Pharmacy, Al‑Quds University, Abu‑Deis 144, Palestine, Research Center, Holy Family Hospital, Nazareth 1600000, Israel, Molecular Genetics and Virology Laboratory, Qasemi Research Center, Faculty of Science, Al‑Qasemi Academic College, Baka El‑Garbiah 3010000, Israel, Geriatric Department, Holy Family Hospital, Nazareth 16000, Israel, Department of Science and Technology, Faculty of Science, Al‑Qasemi Academic College, Baka El‑Garbiah 3010000, Israel
Published online on: March 5, 2025 https://doi.org/10.3892/ol.2025.14962
Article Number: 216
Copyright: © Abu‑Lafi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel (PTX) is among the most widely used antimicrotubular chemotherapy agents available from natural sources. It has a wide range of antitumor effectiveness, particularly against breast, ovarian and lung malignancies. IDD‑1040 is a novel anticancer chemical conjugate that combines lipoic acid with PTX and demonstrates an anticancer efficiency superior to that of PTX alone. The aim of the present study was to investigate the analytical, formulation and pharmacokinetic aspects of IDD‑1040, shedding light on its pharmacological behavior and the possible mechanisms underlying its enhanced anticancer activity. IDD‑1040 was administered to mice as an intravenous bolus, and the pharmacokinetic parameters were determined over the following 7 days. The results revealed a total clearance of 1.689 l/h.kg, volume of distribution of 1.93 l/kg, average half‑life of 1.14 h and terminal half‑life of 8.64 h. Notably, the area under the curve of IDD‑1040 was >14‑fold higher than that of PTX, suggesting slower metabolism and that prodrug itself may have antitumor activity. An in vitro tubulin polymerization assay revealed distinct tubulin‑binding characteristics for IDD‑1040 compared with PTX. Due to the poor water solubility of IDD‑1040, a formulation development experiment was conducted. In total, 31 formulations were prepared that became transparent when diluted with water. In addition, some formulations achieved a relatively high drug content (12 mg/g) without the use of surfactants. Moreover, they included fewer excipients compared with the formulations diluted with water, suggesting a promising approach for drug formulation. In summary, IDD‑1040 exhibited extended circulation, efficient tissue distribution and reduced metabolite formation in vitro, warranting further exploration of its mechanisms of action and therapeutic potential. Future studies are recommended to assess the stability, pharmacokinetics and pharmacodynamics of these refined IDD‑1040 formulations to gauge their suitability for clinical application.

View Figures

View References

1	Reyes-Farias M and Carrasco-Pozo C: The anti-cancer effect of quercetin: Molecular implications in cancer metabolism. Int J Mol Sci. 20:31772019. View Article : Google Scholar : PubMed/NCBI
2	Alipour V, Rezapour A, Adel A, Pourtaleb A, Bazrafshan M, Ghaem Mohammadi MS and Jahangiri R: Economical evaluation of cancer types using intensity-modulated radiation therapy compared to 3d conformal radiation therapy: A systematic review. Iran J Public Health. 52:1355–1366. 2023.PubMed/NCBI
3	Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI
4	Manthalkar L, Ajazuddin and Bhattacharya S: Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs. Discov Oncol. 13:1422022. View Article : Google Scholar : PubMed/NCBI
5	Tauro S, Dhokchawle B, Mohite P, Nahar D, Nadar S and Coutinho E: Natural anticancer agents: Their therapeutic potential, challenges,s and promising outcomes. Curr Med Chem. May 2–2023.(Epub ahead of print). PubMed/NCBI
6	Ahmed Khalil A, Rauf A, Alhumaydhi FA, Aljohani ASM, Javed MS, Khan MA, Khan IA, El-Esawi MA, Bawazeer S, Bouyahya A, et al: Recent developments and anticancer therapeutics of paclitaxel: An update. Curr Pharm Des. 28:3363–3373. 2022. View Article : Google Scholar : PubMed/NCBI
7	Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 93:2325–2327. 1971. View Article : Google Scholar : PubMed/NCBI
8	Seidman AD: Single-agent use of Taxol (paclitaxel) in breast cancer. Ann Oncol. 5 (Suppl 6):S17–S22. 1994.PubMed/NCBI
9	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wilkinson SP: The kidney in cirrhosis. Tijdschr Gastroenterol. 19:155–169. 1976.PubMed/NCBI
11	Ozols RF: Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. Ann Oncol. 5 (Suppl 6):S39–S43. 1994.PubMed/NCBI
12	Einzig AI: Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer. Ann Oncol. 5 (Suppl 6):S29–S32. 1994.PubMed/NCBI
13	Johnson DH, Chang AY and Ettinger DS: Taxol (paclitaxel) in the treatment of lung cancer: The eastern cooperative oncology group experience. Ann Oncol. 5 (Suppl 6):S45–S50. 1994.PubMed/NCBI
14	Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, et al: Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015:6909162015.PubMed/NCBI
15	Mukhtar E, Adhami VM and Mukhtar H: Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 13:275–284. 2014. View Article : Google Scholar : PubMed/NCBI
16	Amaya C, Smith ER and Xu XX: Low intensity ultrasound as an antidote to taxane/paclitaxel-induced cytotoxicity. J Cancer. 13:2362–2373. 2022. View Article : Google Scholar : PubMed/NCBI
17	Walker FE: Paclitaxel (TAXOL): Side effects and patient education issues. Semin Oncol Nurs. 9 (Suppl 2):S6–S10. 1993. View Article : Google Scholar : PubMed/NCBI
18	Nagumo Y, Villareal MO, Isoda H and Usui T: RSK4 confers paclitaxel resistance to ovarian cancer cells, which is resensitized by its inhibitor BI-D1870. Biochem Biophys Res Commun. 679:23–30. 2023. View Article : Google Scholar : PubMed/NCBI
19	Januškevičienė I and Petrikaitė V: Interaction of phenotypic sublines isolated from triple-negative breast cancer cell line MDA-MB-231 modulates their sensitivity to paclitaxel and doxorubicin in 2D and 3D assays. Am J Cancer Res. 13:3368–3383. 2023.PubMed/NCBI
20	Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M and Getzenberg RH: Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J Cell Biochem. 112:2125–2137. 2011. View Article : Google Scholar : PubMed/NCBI
21	Patel A, Kalachand R, Busschots S, Doherty B, Kapros E, Lawlor D, Hall N and Stordal BK: Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 7:CD0087662022.PubMed/NCBI
22	Wang L, Chen H, Wang F and Zhang X: The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv. 19:147–161. 2022. View Article : Google Scholar : PubMed/NCBI
23	Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM and Teng NNH: Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol. 126:118–123. 2012. View Article : Google Scholar : PubMed/NCBI
24	Nakamura J, Nakajima N, Matsumura K and Hyon SH: Water-soluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res. 30:903–909. 2010.PubMed/NCBI
25	Falah M, Rayan M and Rayan A: A novel paclitaxel conjugate with higher efficiency and lower toxicity: A new drug candidate for cancer treatment. Int J Mol Sci. 20:49652019. View Article : Google Scholar : PubMed/NCBI
26	Shelanski ML, Gaskin F and Cantor CR: Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci USA. 70:765–768. 1973. View Article : Google Scholar : PubMed/NCBI
27	Lee JC and Timasheff SN: In vitro reconstitution of calf brain microtubules: Effects of solution variables. Biochemistry. 16:1754–1764. 1977. View Article : Google Scholar : PubMed/NCBI
28	Liu X, Sun J, Chen X, Wang S, Scott H, Zhang X and Zhang Q: Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. J Pharm Pharmacol. 64:775–782. 2012. View Article : Google Scholar : PubMed/NCBI
29	Shin HC, Cho H, Lai TC, Kozak KR, Kolesar JM and Kwon GS: Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release. 163:93–99. 2012. View Article : Google Scholar : PubMed/NCBI
30	Andersson BS and Way C: Parenternal Paclitaxel in a stable non-toxic formulation. Patent US5877205A. Filed June 28 1996; issued March 2, 1999.